Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy

ABSTRACT Background Programmed cell death protein‐1 (PD1) antibodies are currently the standard treatment for resected high‐risk melanoma, yet recurrence rate remains high. Objectives This real‐life observational study aimed to describe the outcomes of patients with resected high‐risk melanoma follo...

Full description

Saved in:
Bibliographic Details
Main Authors: Liza Benzoni, Anaïs Eberhardt, Sarah Milley, Safa Idoudi, Camille Trefcon, Nicolas Romain‐Scelle, Luc Thomas, Stéphane Dalle
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.70432
Tags: Add Tag
No Tags, Be the first to tag this record!